The Promise of an HIV Vaccine



The HCPLive Peer Exchange: Optimizing Outcomes in HIV Treatment features insight and opinion on the latest developments in HIV research, diagnosis, and management from leading physician specialists.

This Peer Exchange is moderated by Paul Doghramji, MD, who is a family physician at Collegeville Family Practice in Collegeville, PA, and Medical Director of health services at Ursinus College, also in Collegeville, PA.

The panelists are:

  • Alfred A. DeLuca, MD, Infectious Disease Specialist at CentraState Healthcare System in Manalapan, NJ
  • Ian Frank, MD, Director of Anti-Retroviral Clinical Research and Director of Clinical Core at Penn Center for AIDS Research, and Professor of Medicine at the Hospital of the University of Pennsylvania in Philadelphia, PA
  • Paul Sax, MD, Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Division of Infectious Diseases and the HIV Program at Brigham and Women's Hospital, in Boston, MA

In this segment, the panelists discuss current efforts to develop a safe and effective HIV vaccine.

Dr. Frank noted that there is a lot of work going on in the field of HIV vaccine development right now, specifically mentioning the RV144 vaccine study (also known at the Phase III HIV Vaccine Trial) that was published in The New England Journal of Medicine. That trial, conducted with more than 16,000 volunteers in Thailand, was the largest HIV vaccine trial conducted in humans. According to Dr. Frank, it showed a modest reduction in HIV acquisition, using vaccines that were not thought to be very effective. From the Thai study, he said that we now know “some immunologic factors that correlated with protection from HIV acquisition,” and now the field is focused on “trying to develop vaccines that would mimic the same kind of immune responses that were seen in that study in a higher proportion of the population and to a greater magnitude.”

However, Dr. Frank said there are many reasons to be pessimistic that it’s even possible to develop an effective HIV vaccine, certainly within the next 10 years. In the meantime, he said there is another study that is attempting to duplicate the Thai study, and there is talk of doing a prevention trial using passive immunotherapy in which individuals will be given antibodies by infusion or by injection to see if that strategy will prevent HIV acquisition.

Dr. Frank said that “Obviously, that is not going to be a strategy that is going to be applied to the population at large, but it will be a very important proof of principle study to demonstrate that neutralizing antibodies can prevent the acquisition of HIV.”

As to the challenges associated with developing an effective HIV vaccine, Dr. Sax said that the fundamental problem is that the main target of HIV is the CD-4 cell, and the question for researchers is “What is it that would provide a neutralizing antibody at a level that’s protective, at the mucosa that’s protective from injection drug use or exposure to blood?” He said investigators have not been able to find a consistent neutralizing antibody or ways to generate it in people, in part because “the surface of the virus changes a lot.”

Related Videos
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication
Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660
Paul Feuerstadt, MD: Administering RBX2660 With a Colonoscopy
Jessica Allegretti, MD, MPH: Evaluating the First Few Months of RBX2660
Naim Alkhouri, MD: Improving NASH Diagnosis With FibroScan
Sahil Khanna, MBBS, MS: Reaction to the Approval of Vowst for rCDI
Esther Ellen Freeman, MD, PhD: Current Mpox Impact on the Skin
© 2023 MJH Life Sciences

All rights reserved.